Berbamine dihydrochloride

Berbamine dihydrochloride, a natural compound derived from the Berberis amurensis plant, has been shown to exhibit antitumor activity in several Ys. (In Vitro) :Berbamine, a novel NF-κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Berbamine treatment leads to increased expression of A20, down-regulation of IKKα, p-IκBα, and follows by inhibition of p65 nuclear localization. As a result, NF-κB downstream targets such as cyclin D1, Bcl-xL, Bid and survivin are down-regulated. To determine whether Berbamine has growth inhibitory effect on myeloma cells, KM3 cells are treated with Berbamine at various concentrations for 24, 48, and 72 h, respectively, and then cell viability is assessed by MTT assays. Berbamine inhibits the growth of KM3 cells in a dose- and time-dependent manner, and the IC50 values are 8.17 μg/mL, 5.09 μg/mL, and 3.84 μg/mL for treatment of 24, 48, and 72 h, respectively. In contrast, IC50 value of Berbamine for normal hematopoietic cells is 185.20 μg/mL at 48 h. (In Vivo) :Berbamine (BBM) is a natural bisbenzylisoquinoline product isolated from traditional Chinese herbal medicine Berberis amurensis and has been used to treat inflammatory and other diseases.The anti-tumor effects of Berbamine are determined on a xenograft animal model. Two liver cancer cell lines, Huh7 (epithelial) and SK-Hep-1 (mesenchymal-like), are inoculated into NOD/SCID mice by subcutaneous injection. The oral Berbamine treatment greatly suppresses the growth of Huh7 xenografted tumors over the time and leads to a tumor reduction by 70% based on the tumor weight. The growth of SK-Hep-1 cells in NOD/SCID mice is less sensitive to Berbamine than that of Huh7. There is a significant suppression of the growth of the SK-Hep-1 xenograft with more than 50% reduction of the tumor weight.